CN106456795A - 靶向治疗学 - Google Patents

靶向治疗学 Download PDF

Info

Publication number
CN106456795A
CN106456795A CN201580022696.0A CN201580022696A CN106456795A CN 106456795 A CN106456795 A CN 106456795A CN 201580022696 A CN201580022696 A CN 201580022696A CN 106456795 A CN106456795 A CN 106456795A
Authority
CN
China
Prior art keywords
sdc
trap
bound fraction
hsp90
dalton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580022696.0A
Other languages
English (en)
Chinese (zh)
Inventor
D.U.基马纳马达
英伟文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of CN106456795A publication Critical patent/CN106456795A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immunology (AREA)
CN201580022696.0A 2014-03-03 2015-03-03 靶向治疗学 Pending CN106456795A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947108P 2014-03-03 2014-03-03
US61/947108 2014-03-03
PCT/US2015/018442 WO2015134464A2 (en) 2014-03-03 2015-03-03 Targeted therapeutics

Publications (1)

Publication Number Publication Date
CN106456795A true CN106456795A (zh) 2017-02-22

Family

ID=54055980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580022696.0A Pending CN106456795A (zh) 2014-03-03 2015-03-03 靶向治疗学

Country Status (10)

Country Link
US (2) US10232049B2 (cg-RX-API-DMAC7.html)
EP (1) EP3129064B1 (cg-RX-API-DMAC7.html)
JP (2) JP6576942B6 (cg-RX-API-DMAC7.html)
KR (1) KR20160126078A (cg-RX-API-DMAC7.html)
CN (1) CN106456795A (cg-RX-API-DMAC7.html)
AU (1) AU2015224576A1 (cg-RX-API-DMAC7.html)
CA (1) CA2941618A1 (cg-RX-API-DMAC7.html)
IL (1) IL247624A0 (cg-RX-API-DMAC7.html)
MA (1) MA39481A (cg-RX-API-DMAC7.html)
WO (1) WO2015134464A2 (cg-RX-API-DMAC7.html)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512821A (zh) * 2017-09-18 2019-03-26 无锡富泽药业有限公司 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用
CN110698491A (zh) * 2018-12-21 2020-01-17 西安交通大学 2-(喜树碱-10-氧基)乙酰胺类化合物和应用
CN110769857A (zh) * 2017-06-20 2020-02-07 塔弗达治疗有限公司 包含靶向治疗剂的联合疗法
CN111499623A (zh) * 2020-04-01 2020-08-07 南京缘聚医药科技有限公司 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
CN111511364A (zh) * 2017-06-20 2020-08-07 马德里加尔制药公司 靶向治疗剂
CN115650975A (zh) * 2022-08-23 2023-01-31 四川大学华西医院 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
WO2023016075A1 (zh) * 2021-08-09 2023-02-16 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
CN116354933A (zh) * 2021-12-27 2023-06-30 中国海洋大学 作为雄激素受体调节剂的杂环化合物及其应用
CN117720514A (zh) * 2023-03-31 2024-03-19 福建医科大学 一种基于分子胶原理降解Hsp90的化合物、其制备方法及其在治疗肿瘤中的应用
WO2024197429A1 (zh) * 2023-03-24 2024-10-03 青岛普泰科生物医药科技有限公司 作为雄激素受体调节剂的杂环化合物及其应用
WO2024199473A1 (en) * 2023-03-31 2024-10-03 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
WO2025199665A1 (en) * 2024-03-23 2025-10-02 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
RU2855694C2 (ru) * 2021-08-09 2026-02-02 Шанхай Майус Фармасьютикал Ко. Лтд. Дигидро-2н-изоиндольный сложный эфир

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39483A (fr) * 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
US11491145B2 (en) * 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
BR112020023136A2 (pt) 2018-05-14 2021-02-09 Nuvation Bio Inc. compostos de alvo de receptor de hormônio nuclear anticâncer
JP2021525766A (ja) * 2018-06-01 2021-09-27 ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. 併用療法
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
AU2020272861A1 (en) * 2019-04-10 2021-10-07 Dana-Farber Cancer Institute, Inc. Degraders of fibroblast growth factor receptor 2 (FGFR2)
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
CN110003181B (zh) * 2019-05-22 2020-08-28 北京凯恩梅格医药科技有限公司 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用
US12616670B2 (en) * 2020-03-23 2026-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2022235585A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641117A (zh) * 2007-03-05 2010-02-03 协和发酵麒麟株式会社 药物组合物
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates
WO2012096919A1 (en) * 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
AU769235B2 (en) 1999-04-09 2004-01-22 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Hsp90インヒビターの使用により細胞毒性剤の効力を増強させる方法
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
US6759416B2 (en) 2002-08-06 2004-07-06 Panorama Research, Inc. Anticancer conjugates of camptothecin and unsaturated fatty acids
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
CA2549463A1 (en) 2002-12-12 2004-07-01 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
JP2007530596A (ja) 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007053792A2 (en) 2005-11-05 2007-05-10 Amplyx Pharmaceuticals, Inc. Improving the pharmacokinetics of protease inhibitors and other drugs
US8293726B2 (en) 2005-12-02 2012-10-23 Vianova Labs, Inc. Treatment of cancer and other diseases
GB0526615D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
TWI490212B (zh) 2006-05-25 2015-07-01 Synta Pharmaceuticals Corp 調節hsp90活性之三唑化合物
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
WO2009009067A2 (en) 2007-07-09 2009-01-15 Kwon Glen S Micelle encapsulation of theropeutic agents
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
WO2010028389A1 (en) 2008-09-08 2010-03-11 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
WO2011116181A1 (en) 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
JP5675619B2 (ja) 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
WO2010056590A2 (en) 2008-11-14 2010-05-20 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
WO2011133879A2 (en) 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
CN107011311A (zh) 2010-10-22 2017-08-04 斯特拉斯堡大学 用于治疗HSP90相关病状的Pochoxime缀合物
GB201106814D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
US20140243239A1 (en) * 2011-10-12 2014-08-28 University Of North Carolina At Chapel Hill Multiplexed kinase inhibitor beads and uses thereof
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2865021C (en) * 2012-02-23 2020-06-30 Bayer Intellectual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3082957B1 (en) 2013-12-20 2022-04-06 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641117A (zh) * 2007-03-05 2010-02-03 协和发酵麒麟株式会社 药物组合物
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates
WO2012096919A1 (en) * 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
WO2013158644A2 (en) * 2012-04-16 2013-10-24 Synta Pharmaceuticals Corp. Targeted therapeutics

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769857A (zh) * 2017-06-20 2020-02-07 塔弗达治疗有限公司 包含靶向治疗剂的联合疗法
CN111511364A (zh) * 2017-06-20 2020-08-07 马德里加尔制药公司 靶向治疗剂
CN109512821B (zh) * 2017-09-18 2021-06-08 无锡富泽药业有限公司 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用
CN109512821A (zh) * 2017-09-18 2019-03-26 无锡富泽药业有限公司 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用
CN110698491A (zh) * 2018-12-21 2020-01-17 西安交通大学 2-(喜树碱-10-氧基)乙酰胺类化合物和应用
CN111499623A (zh) * 2020-04-01 2020-08-07 南京缘聚医药科技有限公司 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途
WO2023016075A1 (zh) * 2021-08-09 2023-02-16 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
RU2855694C2 (ru) * 2021-08-09 2026-02-02 Шанхай Майус Фармасьютикал Ко. Лтд. Дигидро-2н-изоиндольный сложный эфир
CN116354933B (zh) * 2021-12-27 2025-06-20 青岛普泰科生物医药科技有限公司 作为雄激素受体调节剂的杂环化合物及其应用
CN116354933A (zh) * 2021-12-27 2023-06-30 中国海洋大学 作为雄激素受体调节剂的杂环化合物及其应用
CN115650975A (zh) * 2022-08-23 2023-01-31 四川大学华西医院 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用
WO2024197429A1 (zh) * 2023-03-24 2024-10-03 青岛普泰科生物医药科技有限公司 作为雄激素受体调节剂的杂环化合物及其应用
WO2024199473A1 (en) * 2023-03-31 2024-10-03 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
CN117720514A (zh) * 2023-03-31 2024-03-19 福建医科大学 一种基于分子胶原理降解Hsp90的化合物、其制备方法及其在治疗肿瘤中的应用
WO2025199665A1 (en) * 2024-03-23 2025-10-02 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation

Also Published As

Publication number Publication date
WO2015134464A3 (en) 2015-10-29
EP3129064A2 (en) 2017-02-15
CA2941618A1 (en) 2015-09-11
MA39481A (fr) 2015-09-11
US20170049899A1 (en) 2017-02-23
JP6576942B2 (ja) 2019-09-18
US20190060478A1 (en) 2019-02-28
JP2019196406A (ja) 2019-11-14
US10675360B2 (en) 2020-06-09
JP6576942B6 (ja) 2019-11-27
WO2015134464A2 (en) 2015-09-11
US10232049B2 (en) 2019-03-19
EP3129064B1 (en) 2020-01-01
JP2017507150A (ja) 2017-03-16
IL247624A0 (en) 2016-11-30
AU2015224576A1 (en) 2016-09-22
EP3129064A4 (en) 2017-10-25
KR20160126078A (ko) 2016-11-01

Similar Documents

Publication Publication Date Title
JP6949911B2 (ja) 標的化治療薬
US10675360B2 (en) Targeted therapeutics
US9956293B2 (en) Targeted therapeutics
CA2923829A1 (en) Targeted therapeutics
HK1231766A1 (en) Targeted therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: MADRIGAL PHARMACEUTICALS INC.

Address before: Massachusetts, USA

Applicant before: Synta Pharmaceuticals, Corp.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: American Pennsylvania

Applicant after: MADRIGAL PHARMACEUTICALS INC.

Address before: Massachusetts, USA

Applicant before: MADRIGAL PHARMACEUTICALS INC.

CB02 Change of applicant information
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1231766

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20170222

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1231766

Country of ref document: HK